David King, MD - Minnesota Oncology

Dr. David M. King

Claim this profile

Park Nicollet Clinic - Saint Louis Park

Expert in Lung Cancer
Expert in Breast Cancer
104 reported clinical trials
167 drugs studied

About David M. King

Education:

  • Graduated from the University of Boulder School of Medicine, Boulder, CO.
  • Completed Residency and Fellowship at the University of Wisconsin Medical School, Madison, WI.

Experience:

  • Specializes in Medical Oncology & Hematology.
  • Focus areas include Breast Cancer, Melanoma, and Prostate Cancer.
  • Holds Board Certifications in Medical Oncology and Internal Medicine.
  • Member of the American Society of Clinical Oncology (ASCO) and the American Society for Cancer Research.

Area of expertise

1Lung Cancer
Global Leader
David M. King has run 17 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Breast Cancer
Global Leader
David M. King has run 16 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage II
HER2 positive

Affiliated Hospitals

Image of trial facility.
Park Nicollet Clinic - Saint Louis Park
Image of trial facility.
Regions Hospital

Clinical Trials David M. King is currently running

Image of trial facility.

Financial Navigation

for Cancer Patients

This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.
Recruiting1 award N/A
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

More about David M. King

Clinical Trial Related8 years of experience running clinical trials · Led 104 trials as a Principal Investigator · 45 Active Clinical Trials
Treatments David M. King has experience with
  • Nivolumab
  • Carboplatin
  • Paclitaxel
  • Pembrolizumab
  • Radiation Therapy
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does David M. King specialize in?
Is David M. King currently recruiting for clinical trials?
Are there any treatments that David M. King has studied deeply?
What is the best way to schedule an appointment with David M. King?
What is the office address of David M. King?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security